Investing.com - Axonics Modulation Technologies reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. Axonics Modulation...
Axonics, Inc. (AXNX) reported Q3 EPS of ($0.34), $0.13 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $70.4 million versus the consensus estimate...
Axonics, Inc. is a medical technology company. It is engaged in developing and commercializing products for patients with bladder and bowel dysfunction. The bladder and bowel dysfunction includes implantable sacral neuromodulation (SNM) systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and non-obstructive urinary retention (UR), and a urethral bulking agent to treat female stress urinary incontinence (SUI). It has designed and developed the rechargeable sacral neuromodulation (SNM) system (r-SNM System), which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. It has two relating to its r-SNM System, a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. It offers urethral bulking agent, Bulkamid for stress urinary incontinence.
|Average||83.56 (+45.77% Upside)|
|No. of Analysts||9|